Beijing Hotgen Biotech Co Ltd (688068) — Cash Flow Reinvestment Rate

Latest as of September 2025: 4.82x

Beijing Hotgen Biotech Co Ltd (688068) has a Cash Flow Reinvestment Rate of 4.82x as of September 2025, reinvesting CN¥14.73 Million (capex CN¥14.73 Million ) from operating cash flow of CN¥3.05 Million. Check Beijing Hotgen Biotech Co Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

4.82x
(Capex + Investments) / Operating CF

Total Reinvested

CN¥14.73 Million
Capex + Investments

Operating Cash Flow

CN¥3.05 Million
CNY

Capital Expenditures

CN¥14.73 Million
CNY

Beijing Hotgen Biotech Co Ltd Cash Flow Reinvestment Rate (2016–2022)

Historical reinvestment intensity for Beijing Hotgen Biotech Co Ltd across 7 annual periods. Explore Beijing Hotgen Biotech Co Ltd cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Beijing Hotgen Biotech Co Ltd (2016–2022)

Year-by-year capital reinvestment analysis for Beijing Hotgen Biotech Co Ltd. For live market cap and broader valuation context, see 688068 stock market capitalisation.

Year Reinvestment Rate Total Reinvested (CNY) Operating CF Capex YoY Change
2022 1.73x CN¥1.70 Billion CN¥978.75 Million CN¥565.21 Million ▲ +159.5%
2021 0.67x CN¥1.77 Billion CN¥2.64 Billion CN¥398.86 Million ▼ -92.9%
2020 9.35x CN¥1.54 Billion CN¥164.62 Million CN¥172.27 Million ▼ -87.6%
2019 75.11x CN¥1.45 Billion CN¥19.37 Million CN¥88.48 Million ▲ +193.5%
2018 25.59x CN¥1.41 Billion CN¥55.04 Million CN¥42.00 Million ▲ +330.0%
2017 5.95x CN¥136.61 Million CN¥22.95 Million CN¥69.05 Million ▲ +546.2%
2016 0.92x CN¥41.95 Million CN¥45.54 Million CN¥21.18 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow